Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled … – MarketWatch (press release)

Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled
MarketWatch (press release)
"We are strongly committed to advancing a pipeline of iCALM therapies to treat chronic respiratory diseases, including COPD, asthma and cystic fibrosis." "iCALM's ability to limit allergen-induced eosinophilic airway inflammation in this trial is

and more »

View full post on asthma – Google News

Merck Announces Presentation of Phase III Investigational Studies Evaluating … – MarketWatch (press release)

Merck Announces Presentation of Phase III Investigational Studies Evaluating
MarketWatch (press release)
DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the

and more »

View full post on asthma – Google News